Choose a language and wait for the translated text.
Shots:
Abbott has initiated the CROWN-MV trial to evaluate its Cephea Mitral Valve System, designed to offer a minimally invasive, catheter-based valve replacement option, in patients with symptomatic mitral valve disease who are not candidates for surgery or transcatheter repair
The study will enroll ~585 patients across the US, Canada and Europe with moderate-to-severe or severe mitral regurgitation or mitral annular calcification
First 30-day early feasibility study results for the third-generation delivery system, assessing mitral regurgitation reduction and quality-of-life improvements, will be presented at TCT 2026
Ref: PRnewswire | Image: Abbott | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
The post Abbott Initiates Pivotal Trial of Cephea Mitral Valve Replacement System appeared first on PharmaShots.
